Mirae Asset Global Investments Co. Ltd. Grows Position in Cencora, Inc. (NYSE:COR)

Mirae Asset Global Investments Co. Ltd. increased its position in Cencora, Inc. (NYSE:COR - Free Report) by 15.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,037 shares of the company's stock after buying an additional 4,283 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Cencora were worth $7,233,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Stratos Wealth Partners LTD. bought a new stake in Cencora in the fourth quarter valued at approximately $205,000. E. Ohman J or Asset Management AB lifted its position in Cencora by 4.0% in the fourth quarter. E. Ohman J or Asset Management AB now owns 7,800 shares of the company's stock valued at $1,753,000 after purchasing an additional 300 shares during the last quarter. Mather Group LLC. lifted its position in Cencora by 2.3% in the fourth quarter. Mather Group LLC. now owns 2,615 shares of the company's stock valued at $588,000 after purchasing an additional 58 shares during the last quarter. Childress Capital Advisors LLC raised its holdings in shares of Cencora by 3.5% during the fourth quarter. Childress Capital Advisors LLC now owns 1,572 shares of the company's stock valued at $353,000 after acquiring an additional 53 shares in the last quarter. Finally, Oregon Pacific Wealth Management LLC bought a new position in shares of Cencora during the fourth quarter valued at approximately $281,000. Institutional investors own 97.52% of the company's stock.

Cencora Stock Up 0.2 %

Shares of NYSE COR traded up $0.48 during trading on Tuesday, reaching $246.86. The company had a trading volume of 1,076,644 shares, compared to its average volume of 1,476,687. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $262.26. The stock has a market cap of $47.71 billion, a PE ratio of 35.11, a P/E/G ratio of 1.49 and a beta of 0.49. The business's 50-day moving average is $238.86 and its 200 day moving average is $237.03. The company has a quick ratio of 0.53, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts forecast that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend is Friday, February 14th. Cencora's payout ratio is currently 31.29%.

Insider Activity

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now owns 306,752 shares of the company's stock, valued at $74,283,064.32. This trade represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock valued at $17,790,912 over the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently commented on COR. JPMorgan Chase & Co. upped their target price on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Evercore ISI upped their price target on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Mizuho initiated coverage on Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price target on the stock. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Finally, Wells Fargo & Company upped their price target on Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a research note on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat, Cencora presently has an average rating of "Moderate Buy" and a consensus target price of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.